scholarly journals Contribution of Variants in the Small Heterodimer Partner Gene to Birthweight, Adiposity, and Insulin Levels: Mutational Analysis and Association Studies in Multiple Populations

Diabetes ◽  
2003 ◽  
Vol 52 (5) ◽  
pp. 1288-1291 ◽  
Author(s):  
C.-C. C. Hung ◽  
I. S. Farooqi ◽  
K. Ong ◽  
J.'a. Luan ◽  
J. M. Keogh ◽  
...  
2009 ◽  
Vol 18 (4) ◽  
pp. 1285-1289 ◽  
Author(s):  
Kevin M. Waters ◽  
Loic Le Marchand ◽  
Laurence N. Kolonel ◽  
Kristine R. Monroe ◽  
Daniel O. Stram ◽  
...  

2015 ◽  
pp. btv448 ◽  
Author(s):  
Alencar Xavier ◽  
Shizhong Xu ◽  
William M. Muir ◽  
Katy Martin Rainey

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Belinda Yau ◽  
Zachary Blood ◽  
Yousun An ◽  
Zhiduan Su ◽  
Melkam A. Kebede

AbstractA threonine-to-Isoleucine (Thr52Ile) mutation within the pro-domain of the Sorcs1 gene was positionally cloned as the gene underlying a quantitative trait locus that affects fasting insulin levels in mice. In humans, genome-wide association studies and linkage studies have shown that SORCS1 is associated with diabetes and all of diabetes complications. We have recently shown that deletion of Sorcs1 in mice made obese with the leptinob mutation results in diabetes and an insulin granule stability defect. This present study investigates the functional consequence of the Sorcs1 Thr52Ile mutation in the rat INS1 β-cell line expressing either the wildtype or mutant Sorcs1 allele. We find that Sorcs1 Thr52Ile mutation is associated with increased basal insulin secretion, reduced glucose-stimulated insulin secretion and decreased insulin content in INS1 cells. Moreover, expression of Thr52Ile causes differential processing of the Sorcs1 protein resulting in the formation of an additional 90 kDa mutant form of the protein. The mutant form of the protein is localised to the ER, retains its pro-domain, and concurrently reduces expression of the functional mature 130 kDa Sorcs1 protein. These findings provide a mechanistic clue to why this specific allelic variation in Sorcs1 was associated with reduced insulin levels and type 2 diabetes.


2017 ◽  
Author(s):  
RC Richmond ◽  
KH Wade ◽  
L Corbin ◽  
J Bowden ◽  
G Hemani ◽  
...  

AbstractInsulin may serve as a key causal agent which regulates fat accumulation in the body. Here we assessed the causal relationship between fasting insulin and adiposity using publicly-available results from two large-scale genome-wide association studies for body mass index and fasting insulin levels in a two-sample, bidirectional Mendelian Randomized approach. This approach is only valid on the condition that the two instruments are independent of one another. In analysis excluding overlapping loci, there was an increase of 0.20 (0.17, 0.23) log pmol/L fasting insulin per SD increase in BMI (P= 2.80 x 10−36), while there was a null effect of fasting insulin on BMI, with a 0.01 (−0.39, 0.38) SD decrease in BMI per log pmol/L increase in fasting insulin (P= 0.98). Furthermore, a high degree of heterogeneity in the causal estimates was obtained from the insulin-related variants, which may be attributed to varying mechanisms of action of the insulin-associated variants. Results were largely consistent when an Egger regression technique and weighted median and mode estimators were applied. Findings suggest that the positive correlation between adiposity and fasting insulin levels are at least in part explained by the causal effect of adiposity on increasing insulin, rather than vice versa.


2006 ◽  
Vol 38 (11) ◽  
pp. 1298-1303 ◽  
Author(s):  
Paul I W de Bakker ◽  
Noël P Burtt ◽  
Robert R Graham ◽  
Candace Guiducci ◽  
Roman Yelensky ◽  
...  

2008 ◽  
Vol 29 (11) ◽  
pp. E271-E277 ◽  
Author(s):  
Mayumi Enya ◽  
Yukio Horikawa ◽  
Eiji Kuroda ◽  
Kayoko Yonemaru ◽  
Naoko Tonooka ◽  
...  

2001 ◽  
Vol 98 (2) ◽  
pp. 575-580 ◽  
Author(s):  
H. Nishigori ◽  
H. Tomura ◽  
N. Tonooka ◽  
M. Kanamori ◽  
S. Yamada ◽  
...  

2019 ◽  
Vol 37 (04) ◽  
pp. 174-181 ◽  
Author(s):  
Delanie B. Macedo ◽  
Ursula B. Kaiser

AbstractThe factors that trigger human puberty are among the central mysteries of reproductive biology. Several approaches, including mutational analysis of candidate genes, large-scale genome-wide association studies, whole exome sequencing, and whole genome sequencing have been performed in attempts to identify novel genetic factors that modulate the human hypothalamic–pituitary–gonadal axis to result in premature sexual development. Genetic abnormalities involving excitatory and inhibitory pathways regulating gonadotropin-releasing hormone secretion, represented by the kisspeptin (KISS1 and KISS1R) and makorin ring finger 3 (MKRN3) systems, respectively, have been associated with sporadic and familial cases of central precocious puberty (CPP). More recently, paternally inherited genetic defects of DLK1 were identified in four families with nonsyndromic CPP and a metabolic phenotype. DLK1 encodes a transmembrane protein that is important for adipose tissue homeostasis and neurogenesis and is located in the imprinted chromosome 14q32 region associated with Temple syndrome. In this review, we highlight the clinical and genetic features of patients with CPP caused by DLK1 mutations and explore the involvement of Notch signaling and DLK1 in the control of pubertal onset.


Diabetes ◽  
2003 ◽  
Vol 52 (5) ◽  
pp. 1276-1279 ◽  
Author(s):  
S. M.S. Mitchell ◽  
M. N. Weedon ◽  
K. R. Owen ◽  
B. Shields ◽  
B. Wilkins-Wall ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document